A detailed history of Commonwealth Equity Services, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 198,037 shares of TGTX stock, worth $6.95 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
198,037
Previous 186,994 5.91%
Holding current value
$6.95 Million
Previous $3.33 Million 39.22%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$17.21 - $25.28 $190,050 - $279,167
11,043 Added 5.91%
198,037 $4.63 Million
Q2 2024

Jul 31, 2024

BUY
$13.32 - $19.19 $31,435 - $45,288
2,360 Added 1.28%
186,994 $3.33 Million
Q1 2024

Apr 29, 2024

BUY
$13.02 - $21.3 $1,614 - $2,641
124 Added 0.07%
184,634 $2.81 Million
Q4 2023

Feb 06, 2024

BUY
$6.68 - $18.81 $14,094 - $39,689
2,110 Added 1.16%
184,510 $3.15 Million
Q3 2023

Oct 23, 2023

BUY
$8.36 - $26.5 $249,780 - $791,767
29,878 Added 19.59%
182,400 $1.53 Million
Q2 2023

Aug 10, 2023

SELL
$15.48 - $35.0 $41,718 - $94,325
-2,695 Reduced 1.74%
152,522 $3.79 Million
Q1 2023

May 11, 2023

BUY
$10.23 - $19.34 $133,061 - $251,555
13,007 Added 9.15%
155,217 $2.33 Million
Q4 2022

Feb 07, 2023

BUY
$5.01 - $11.83 $114,959 - $271,451
22,946 Added 19.24%
142,210 $1.68 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $34,389 - $63,210
7,525 Added 6.73%
119,264 $706,000
Q2 2022

Jul 19, 2022

BUY
$3.74 - $10.66 $364,242 - $1.04 Million
97,391 Added 678.78%
111,739 $474,000
Q1 2022

May 04, 2022

BUY
$7.81 - $20.45 $33,348 - $87,321
4,270 Added 42.37%
14,348 $136,000
Q4 2021

Jan 31, 2022

SELL
$15.2 - $35.51 $23,924 - $55,892
-1,574 Reduced 13.51%
10,078 $191,000
Q3 2021

Oct 29, 2021

BUY
$21.78 - $40.45 $121,880 - $226,358
5,596 Added 92.4%
11,652 $387,000
Q2 2021

Aug 11, 2021

BUY
$32.5 - $48.96 $196,820 - $296,501
6,056 New
6,056 $234,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.09B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.